Clinical Trials Browser

Carcinoma, Renal Cell

NCT03854474 2026-04-13

Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma

Phase 1/2 Active not recruiting

30 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05808608 2026-04-07

A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma

Phase 1/2 Active not recruiting

37 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT04708470 2026-04-06

A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers

Phase 1/2 Active not recruiting

55 enrolled

GastrointestinalGenitourinaryGynecologicHead & Neck

Anus Neoplasms, Uterine Cervical Neoplasms, Colonic Neoplasms, Head and Neck Neoplasms, Oropharyngeal Neoplasms, Penile Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms

NCT05562830 2026-04-02

MK-3475-04A

Phase 1/2 Active not recruiting

48 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT03543189 2026-04-01

Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy

Phase 1/2 Active not recruiting

44 enrolled

Genitourinary

Prostatic Diseases, Prostatic Neoplasms

NCT02138734 2026-03-31

A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer

Phase 1/2 Active not recruiting

369 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasms

NCT03473743 2026-03-30

A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer

Phase 1/2 Active not recruiting

125 enrolled 19 charts

Genitourinary

Carcinoma, Transitional Cell

NCT02650401 2026-03-25

STARTRK-NG

Phase 1/2 Active not recruiting

69 enrolled 2 FDA

CNSEndocrineGenitourinaryHead & NeckSarcoma

Thyroid Cancer, Papillary, Brain Neoplasms, Glioma, Medulloblastoma, Neoplasm Metastasis, Wilms Tumor, Neuroblastoma, Recurrence, Salivary Gland Neoplasms, Sarcoma, Sarcoma, Ewing, Central Nervous System Neoplasms, Nephroma, Mesoblastic

NCT05661955 2026-03-20

A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.

Phase 1/2 Active not recruiting

113 enrolled

DermatologicGenitourinary

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Melanoma

NCT06066437 2026-03-05

NeoAdjuvant Theranostic Lutetium Study: The Nautilus Trial

Phase 1/2 Active not recruiting

6 enrolled

Genitourinary

Prostatic Neoplasms

NCT05546268 2026-03-03

Study of Oral MRT-2359 in Selected Cancer Patients

Phase 1/2 Active not recruiting

174 enrolled

BreastGenitourinaryLymphoidThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Prostatic Neoplasms, Lymphoma, Large B-Cell, Diffuse, Small Cell Lung Carcinoma

NCT01684397 2026-02-27

Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer

Phase 1/2 Active not recruiting

51 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT05672459 2026-02-25

A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors

Phase 1/2 Active not recruiting

31 enrolled

Genitourinary

Kidney Neoplasms

NCT02522715 2026-02-24

Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer

Phase 1/2 Active not recruiting

37 enrolled 10 charts

Genitourinary

Prostatic Neoplasms

NCT04471727 2026-02-24

MK-6070-001

Phase 1/2 Active not recruiting

232 enrolled

EndocrineGenitourinaryNETThoracic

Lung Neoplasms, Prostatic Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors, Small Cell Lung Carcinoma

NCT03317392 2026-02-19

Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis

Phase 1/2 Active not recruiting

145 enrolled

Genitourinary

Prostatic Neoplasms

NCT04644068 2026-02-19

PETRA

Phase 1/2 Active not recruiting

702 enrolled

BreastGastrointestinalGenitourinaryGynecologicThoracic

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT06483334 2026-02-18

MK-3475-04C

Phase 1/2 Active not recruiting

38 enrolled

Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Transitional Cell

NCT04506567 2026-02-17

Fractionated and Multiple Dose 225Ac-J591 for Progressive mCRPC

Phase 1/2 Active not recruiting

60 enrolled

Genitourinary

Prostatic Neoplasms

NCT04626479 2026-02-12

MK-3475-03A

Phase 1/2 Active not recruiting

400 enrolled

Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT04478279 2026-02-09

A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors

Phase 1/2 Active not recruiting

125 enrolled

BreastCNSDermatologicGenitourinary

Brain Neoplasms, Breast Neoplasms, Glioblastoma, Melanoma, Prostatic Neoplasms

NCT04946370 2026-02-03

Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer

Phase 1/2 Active not recruiting

37 enrolled

Genitourinary

Prostatic Neoplasms

NCT03474497 2026-01-29

UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade

Phase 1/2 Active not recruiting

18 enrolled 13 charts

DermatologicGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

NCT05968144 2026-01-27

ADRIAN

Phase 1/2 Active not recruiting

30 enrolled

BreastGenitourinary

Frailty, Breast Neoplasms, Prostatic Neoplasms

NCT05468697 2026-01-23

MK-6482-024

Phase 1/2 Active not recruiting

60 enrolled

Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT02473536 2026-01-16

Neo-adjuvant SABR for IVC Tumor Thrombus in Newly Diagnosed RCC

Phase 1/2 Active not recruiting

25 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT05501054 2026-01-14

Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.

Phase 1/2 Active not recruiting

50 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT06305767 2026-01-13

INTerpath-005

Phase 1/2 Active not recruiting

230 enrolled

Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Urinary Bladder Neoplasms

NCT05544552 2026-01-12

SURF301

Phase 1/2 Active not recruiting

310 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasm Metastasis, Urologic Neoplasms

NCT02989584 2026-01-07

A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer

Phase 1/2 Active not recruiting

54 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05826600 2026-01-06

A Study of OMX-0407 in Patients With Previously Treated Solid Tumours That Can't be Removed Surgically

Phase 1/2 Active not recruiting

188 enrolled

GenitourinarySarcoma

Carcinoma, Renal Cell, Hemangiosarcoma

NCT01950351 2025-12-22

Hypofractionated Proton Beam Therapy for Localized Prostate Cancer

Phase 1/2 Active not recruiting

241 enrolled

Genitourinary

Stage I Prostate Adenocarcinoma AJCC v7

NCT05983198 2025-12-22

SatisfACtion

Phase 1/2 Active not recruiting

29 enrolled

Genitourinary

Prostatic Neoplasms

NCT04198766 2025-12-18

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Phase 1/2 Active not recruiting

296 enrolled

DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Lung Neoplasms, Melanoma, Mouth Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Oropharyngeal Neoplasms, Stomach Neoplasms, Neoplasms, Squamous Cell

NCT04863885 2025-12-17

Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients

Phase 1/2 Active not recruiting

46 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05363631 2025-12-10

Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab

Phase 1/2 Active not recruiting

55 enrolled

Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT05367440 2025-12-08

PETRANHA

Phase 1/2 Active not recruiting

174 enrolled

Genitourinary

Prostatic Neoplasms

NCT05682443 2025-12-02

PRESERVE-006

Phase 1/2 Active not recruiting

148 enrolled

Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT04180371 2025-11-17

Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression

Phase 1/2 Active not recruiting

288 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT04561362 2025-11-14

Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies

Phase 1/2 Active not recruiting

329 enrolled

BreastGenitourinaryGynecologic

Urinary Bladder Neoplasms, Breast Neoplasms, Ovarian Neoplasms, Renal Insufficiency, Triple Negative Breast Neoplasms

NCT02420847 2025-11-10

Ixazomib Citrate With Gemcitabine Hydrochloride and Doxorubicin Hydrochloride in Treating Patients With Urothelial Cancer That is Metastatic or Cannot Be Removed by Surgery

Phase 1/2 Active not recruiting

57 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT04074967 2025-11-06

Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab

Phase 1/2 Active not recruiting

70 enrolled

DermatologicGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

NCT03172754 2025-10-29

Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma

Phase 1/2 Active not recruiting

98 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT03217747 2025-10-23

Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies

Phase 1/2 Active not recruiting

173 enrolled 28 charts

Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT05540392 2025-10-10

An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues

Phase 1/2 Active not recruiting

60 enrolled

Genitourinary

Prostatic Neoplasms, Nocturia

NCT06245915 2025-09-22

AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC)

Phase 1/2 Active not recruiting

37 enrolled

Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell, Kidney Neoplasms, Recurrence

NCT03042468 2025-09-17

Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPC

Phase 1/2 Active not recruiting

50 enrolled 19 charts

Genitourinary

Prostatic Neoplasms

NCT03647163 2025-09-16

Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors

Phase 1/2 Active not recruiting

33 enrolled

EndocrineGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Neuroendocrine

NCT05845814 2025-09-10

MK-3475-04B

Phase 1/2 Active not recruiting

390 enrolled

Genitourinary

Carcinoma, Transitional Cell

Clinical Trials

Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer

Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma

A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma

A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers

MK-3475-04A

Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy

A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer

A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer

STARTRK-NG

A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.

NeoAdjuvant Theranostic Lutetium Study: The Nautilus Trial

Study of Oral MRT-2359 in Selected Cancer Patients

Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer

A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors

Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer

MK-6070-001

Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis

PETRA

MK-3475-04C

Fractionated and Multiple Dose 225Ac-J591 for Progressive mCRPC

MK-3475-03A

A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors

Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer

UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade

ADRIAN

MK-6482-024

Neo-adjuvant SABR for IVC Tumor Thrombus in Newly Diagnosed RCC

Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.

INTerpath-005

SURF301

A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer

A Study of OMX-0407 in Patients With Previously Treated Solid Tumours That Can't be Removed Surgically

Hypofractionated Proton Beam Therapy for Localized Prostate Cancer

SatisfACtion

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients

Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab

PETRANHA

PRESERVE-006

Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression

Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies

Ixazomib Citrate With Gemcitabine Hydrochloride and Doxorubicin Hydrochloride in Treating Patients With Urothelial Cancer That is Metastatic or Cannot Be Removed by Surgery

Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab

Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma

Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies

An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues

AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC)

Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPC

Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors

MK-3475-04B